source
- Celea Therapeutics raises $180 million to advance next-generation IPF drug deupirfenidoneCelea Therapeutics, a PureTech Health spinout, announced a $180 million venture round to fund development of its next-generation idiopathic pulmonary fibrosis (IPF) therapy, deupirfenidone. The ro…
- Abiomed recalls Impella CP Sets with SmartAssist over low purge pressure riskAbiomed has issued a recall of specific Impella CP Sets with SmartAssist after discovering that the units do not meet design specifications. The defect can cause low purge pressure events from the…